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OXIDATIVE AND INFLAMMATORY STATUS IN TYPE-2 
DIABETES MELLITUS PATIENTS WITH AND WITHOUT 
CARDIAC COMPLICATIONS 
ABSTRACT 
 
Background and Objective of the study: 
    Diabetes mellitus, a heterogeneous collection of metabolic disorders may be due 
to reduced insulin secretion or decrease in the effectiveness of secreted insulin or a 
combination of both. Increased oxidative stress and inflammation contributes to the 
development and progression of diabetes and its complications. Diabetes 
aggravates other co-morbidities such as obesity, hypertension and dyslipidemia 
which also increase the risk for Cardio Vascular Disease. High-sensitivity C-
reactive protein (hs-CRP) an acute phase protein is considered to be predictor of 
future coronary events. Thiols constitute the major portion of the total body 
antioxidants and they play a significant role in defense against reactive oxygen 
species.  
Objective of this study was to estimate the levels of hsCRP and protein thiols in 
type 2 diabetic patients with and without cardiac complications .In addition this 
study also tries to establish a correlation between glycated haemoglobin, hsCRP 
and protein thiols in both the study groups. 
Material and Methods: 
This is a cross sectional study. Type-2 diabetic patients belonging to the age group 
of 30-75 years were selected from Diabetology OPD and Cardiology ward. HbA1c 
and plasma hsCRP were estimated in 60 type-2 diabetic patients without 
complications and 60 type-2 diabetic patients with cardiac complications. Type-2 
diabetic patients with other complications were excluded. Plasma total protein 
thiols was estimated spectrophotometrically by using Dinitrobenzene (DTNB)-
Ellman’s method, plasma hsCRP was measured by particle enhanced turbidimetric 
assay and HbA1c by turbidimetric inhibition immunoassay.  
Results: 
There was no statistically significant difference between the two study groups with 
regard to age and gender. The mean hsCRP activity in type-2 diabetic patients 
without complications was 0.2885 ±0.26758 and with cardiac complications was 
3.1970±5.83335 which was statistically significant with the p value of 0.000187. 
The p value of HbA1c levels between the two groups was found to be 0.047 which 
was also statistically significant. There was no statistical significance (p value, 
0.530) between the two groups with regard to protein thiols. Further, the Pearson 
correlation analysis showed a significant positive correlation between the blood 
levels of HbA1c with the plasma total protein thiols (p value < 0.001) and hsCRP 
(p value 0.018). In addition there is a very significant positive correlation between 
the plasma levels of hsCRP and the plasma total protein thiols with a p value of  
< 0.001. 
Interpretation and Conclusion: 
Increased HbA1c and plasma hsCRP in type 2 diabetic patients with cardiac 
complications can be attributed to the fact that oxidative stress and inflammation 
due to persistent hyperglycemia play a major role in the pathogenesis of diabetic 
complications. The increase in thiol levels along with hsCRP is due to the 
increased synthesis to compensate for the loss incurred during neutralization of the 
oxidants in Type 2 diabetic patients. 
 
Key words: Diabetes mellitus, Cardiovascular disease, Atherosclerosis, Oxidative 
stress, Inflammation, High sensitivity C reactive protein, Protein thiols 
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1. Introduction: 
     Diabetes mellitus (DM) is a heterogeneous collection of metabolic 
disorder characterized by a state of decreased insulin action which may 
be due to reduced insulin secretion or decrease in the effectiveness of 
secreted insulin or a combination of both.
 
Diabetes mellitus is considered 
to be a state of persistent low grade inflammation which contributes to the 
pathogenesis of disease
1
. Inflammation is a state of local protective 
response to tissue injury
2
. In addition to local response, systemic response 
called as acute-phase response is depicted by the changes in levels of 
acute phase reactants like   C-Reactive Protein(CRP), complement, serum 
amyloid A, haptoglobin and fibrinogen
3
.Patients with diabetes mellitus 
aggravate other co-morbidities like hypertension, obesity and 
dyslipidemia which in turn increase the risk for Cardio Vascular Disease 
(CVD)
4
. 
CRP, an acute phase protein is produced by the liver and their 
levels increase whenever there is instances of inflammation in the body
5
. 
CRP may also rise in acute Coronary Syndrome, arthritis, autoimmune 
disease, inflammatory bowel disease, pancreatitis, colitis and carcinoma. 
CRP testing cannot be used to diagnose specific diseases but serves more 
as a general indicator of inflammation or infection
6
.
 
Numerous 
epidemiologic studies done in United States and Europe have concluded 
2 
 
high-sensitivity C-reactive protein (hs-CRP) to be a predictor of future 
coronary events among apparently healthy individuals
7
.
 
        Increased oxidative stress plays a major role in the progression of 
diabetes and development of complications
8
.Oxidative stress increases 
when the rate of free radical production is increased and/or the 
antioxidant mechanisms are impaired
9
. Free radicals are unstable species 
which are produced continuously during aerobic metabolism. These free 
radicals cause oxidative damage to carbohydrates, proteins, lipids and 
DNA that are normally neutralized by protective antioxidants. The 
imbalance between increased free radical production and protective 
antioxidants to neutralize it, leading to oxidative damage is known as 
oxidative stress. Studies have demonstrated reduced concentration of 
vitamin A, C, E and the antioxidant enzymes like superoxide dismutase 
(SOD), catalase and glutathione peroxidase in type 2 diabetics
10, 11
. 
Incomplete scavenging of reactive free radicals causes oxidation of 
cellular proteins, lipids, nucleic acids and glycoconjugates which in turn 
leads to fragmentation and cross-linking causing extensive pathological 
consequences leading to cell death. Oxidation of glucose and 
glycosylated proteins in type 2 diabetic patients is thought to be the 
reason for increased production of damaging free radicals
12
.
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Thiols are the organic compounds that contain a sulfhydryl group 
(-SH). Thiols form the major portion of the total body antioxidants among 
all other antioxidants and they play an important role in defense against 
reactive oxygen species
13
.The reduced thiol (–SH) groups can exist both 
intracellularly and extracellularly in two forms. They can be either in free 
form as reduced glutathione or can exist as protein bound thiols playing a 
major role in conserving the antioxidant status of the body
14
. Among the 
protein bound thiols, albumin makes the major portion of it, which binds 
to sulfhydryl group at its cys-34 portion
15
. In oxidative stress, protein 
oxidation products are formed early, have greater stability and longer 
lifespan than Reactive Oxygen Species (ROS) and lipid peroxidation 
products. Hence, they are being increasingly used to demonstrate 
oxidative stress in place of lipid peroxidation
16
.  
    This study is done to estimate the levels of  hsCRP and  protein thiols 
in type 2 diabetic patients with and without cardiac complications .In 
addition we also have tried to establish a correlation between glycated 
haemoglobin, hsCRP and  protein thiols in both the study groups. 
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2. Aims and Objectives 
Aim: 
To evaluate the oxidative and inflammatory status in type 2 
diabetic patients with cardiac complications and compare the same with 
type 2 diabetic patients without cardiac complications  
 
Objectives: 
1. To estimate the levels of oxidative marker (Protein thiols) and 
inflammatory marker (hsCRP) in type 2 diabetes mellitus patients with 
and without cardiac complications. 
 
2. To find out the correlation between oxidative, inflammatory markers 
and glycated hemoglobin (HbA1c) in the study groups. 
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3. Review of literature: 
Introduction: 
Diabetes mellitus is a group of metabolic diseases presenting with 
signs and symptoms of hyperglycemia which may be due to defects in 
insulin secretion, insulin action, or both.  
Epidemiology of diabetes mellitus: 
Global prevalence of diabetes mellitus  in adult population (20-79 
years old) is estimated to be around 8.3% with 382 million people 
suffering  from diabetes .North America and the Caribbean region has got 
the highest prevalence of disease  (11%) followed by the Middle East and 
North Africa (9.2%)
17
. Type 2 DM accounts for approximately half of 
adolescent diabetes in the United States, and one-third of these cases were 
undiagnosed
18
.
 
It was estimated that nearly 1 million Indians die due to 
diabetes every year with the average age of onset being 42.5 years and it 
is expected that by 2030 incidence will increase possibly due to increased 
prevalence of obesity and lack of physical activities
19, 20
. Prevalence of 
diabetes mellitus is higher in men less than 60 years of age when 
compared to women at older ages
21
. Majority of people with diabetes are 
in 45 to 64 years of age in developing countries, whereas in developed 
countries most of them are greater than 64 years of age
22
.
 
The prevalence 
6 
 
of Type 2 diabetes is high and it is 4-6 times higher in urban than in rural 
areas of india
23
. 
 
Classification: 
Diabetes mellitus rather than being classified on the basis of age at 
which diabetes has been diagnosed and therapy given to them is now 
classified according to the pathogenesis of disease that leads to increase 
in blood glucose levels. 
Etiological classification of diabetes mellitus
24
: 
• Type I diabetes mellitus is due to β-cell destruction, leading to 
complete or near total insulin deficiency 
• Type II diabetes mellitus is due to variable degrees of resistance to 
insulin action and decreased insulin secretion 
• Gestational diabetes mellitus (GDM) – intolerance to glucose 
developed during the course of pregnancy  
• Other types 
A. Impairment in beta cell function due to genetic defects 
1. Hepatocyte Nuclear Factor -1a, Maturity onset diabetes of the   
     young (MODY3) 
2. Glucokinase (MODY2) 
7 
 
3. Hepatocyte Nuclear Factor-4a (MODY1) 
4. Insulin promoter factor-1 (MODY4) 
5. Hepatocyte Nuclear Factor -1b (MODY5) 
6. NeuroD1 (MODY6) 
7. DNA of mitochondrial origin 
8. Other genetic defects 
 
B. Genetic defects leading to defective insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipoatrophic diabetes 
5. Other genetic defects 
 
C. Diseases of the exocrine pancreas 
1. Pancreatitis 
2. Trauma to pancreas 
3. Malignancy  
4. Cysticfibrosis 
5. Hemochromatosis 
6. Fibrocalculous pancreatopathy 
7. Following Pancreatectomy 
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D. Endocrinopathies 
1. Acromegaly 
2. Cushing’s syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
8. Other disorders 
E. Drug or chemical induced 
1. Vacor 
2. Pentamidine 
3. Nicotinic acid 
4. Corticosteroids 
5. Thyroid hormone 
6. Diazoxide 
7.β-adrenergic agonists 
8. Thiazides 
9. Dilantin 
10.γ-Interferon 
11. Other drugs 
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F. Infections 
1. Congenital rubella 
2. Cytomegalovirus 
3. Other infections 
G. Immune-mediated forms of diabetes 
1. Stiff-man syndrome 
2. Anti-insulin receptor antibodies 
3. Other forms 
H. Other genetic syndromes sometimes associated with diabetes 
1. Down syndrome 
2. Klinefelter syndrome 
3. Turner syndrome 
4. Wolfram syndrome 
5. Friedrich ataxia 
6. Huntington chorea 
7. Laurence-Moon-Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
         10. Prader-Willi syndrome 
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Criteria for diagnosing diabetes mellitus
25
: 
 
• Glycated hemoglobin  ≥  6.5%. or 
• Fasting Plasma Glucose (FPG) ≥ 126 mg/dL or 
• 2-hour plasma post prandial  glucose ≥ 200mg/dL during an Oral 
Glucose Tolerance Test or 
• Random plasma Glucose  ≥  200 mg/dL with signs and symptoms 
of hyperglycemia 
 
Categories with increased risk for diabetes
25
: 
 
• Impaired fasting glucose[IFG]:FPG 100 mg/dL to 125 mg/dL 
• Impaired glucose tolerance [IGT]:2-hour plasma glucose in the 75g 
oral glucose tolerance test 140 mg/dL   to 199 mg/dL 
• Glycated hemoglobin - 5.7-6.4% 
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Type 1 diabetes mellitus: 
 
Type 1 diabetes mellitus primarily due to beta cell destruction can 
be subdivided into  
 - Immune etiology, Type 1A 
- Unknown etiology, Type 1B
 
 
Type 1 diabetes mellitus is due to autoimmune destruction of 
pancreatic beta cells leading to insulin deficiency. The rate of beta cell 
destruction varies among individuals. The major vulnerable gene is the 
Human Leukocyte Antigen gene which codes for major 
histocompatability complex (MHC) class II on chromosome 6 for type 1 
diabetes mellitus. Class II MHC initiates immune response by presenting 
antigens to helper T cells which depends on the composition of amino 
acids on the antigen binding site
26
. In addition to MHC II, multiple gene 
polymorphisms have been reported to increase the risk of type 1A 
diabetes. These include  interferon-induced helicase , preproinsulin, 
Protein tyrosine phosphatase nonreceptor type 22 gene PTPN22, 
Cytotoxic T Lymphocyte Antigen -4, Interleukin 2 receptor (CD25), a 
lectin-like gene (KIA0035), epidermal growth factor receptor family 
ERBB3e, and undefined gene at 12q.Variations in the number of 
nucleotide repeat elements 5` of the insulin gene, PTPN22 gene encoding 
12 
 
a lymphoid specific phosphatase that influences T cell receptor signaling 
are all associated with the development of type 1A diabetes
27
.Greater than 
90% of the patients are positive for auto antibodies to islet cells. They 
include autoantibodies to insulin (IAA), glutamic acid decarboxylase 
(GADA) and islet cells (ICA) 
28
. 
 
Fig 3.1: Pathogenesis of type 1 diabetes mellitus 
 
          
 
Source: Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives 
on disease pathogenesis and treatment. Lancet 2001; 358: 221–229. 
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Type 2 diabetes mellitus: 
Type 2 DM is the most prevalent form of diabetes. It affects greater 
than 90% of the population suffering from diabetes globally. There is a 
rapid increase in the number of diabetic patients and this fiery growth is 
noted in both rural and urban areas. It is characterized by excessive 
hepatic glucose production, variable degree of resistance to insulin action, 
decreased insulin secretion, and abnormalities in fat metabolism. 
Risk factors for type 2 diabetes mellitus
25
: 
Sedentary life, lack of physical activity, diet, lifestyle changes and 
related epidemiological conversion has been established as risk factors 
for type 2 DM. Other major risk factors are listed below. 
• Family history of diabetes mellitus 
• Overweight with Body Mass Index, BMI ≥ 25 kg/m
2
 
• Decreased physical activity 
• Ethnicity  
• Previously identified to have IFG/IGT 
• Blood pressure ≥ 140/90 mm of Hg 
• Triglycerides ≥ 250 mg/dL 
• High Density Lipoprotein (HDL) ≤ 35 mg/dL 
• Previous History of Gestational diabetes mellitus 
14 
 
• Polycystic ovary syndrome 
• Acanthosis nigricans 
 
Pathogenesis of type 2 Diabetes Mellitus: 
Type 2 DM is a progressive multifactorial disease, with insulin 
resistance and decreased activity of beta cells playing major role in the 
pathogenesis of disease. 
Insulin resistance refers to impaired response of the body to either 
exogenously administered insulin or to insulin secreted by the pancreatic 
beta cells endogenously. This is manifested as decrease in insulin 
stimulated glucose transport, metabolism in skeletal muscle and 
adipocytes and by defective suppression of hepatic production of glucose, 
all these leading to hyperglycemia. Genetic susceptibility and obesity 
predisposes to insulin resistance. Mutation in the insulin receptor may 
also interfere with insulin signal transduction pathway. 
Decreased response of the target cells to insulin leads to 
hyperinsulinemia which in turn reduces insulin receptor level and 
tyrosine kinase activity. Defect in phosphatidyl inositol 3- kinase 
signaling reduces Glucose transporter4 (GLUT4) translocation to plasma 
membrane. There is reduced insulin stimulated mitochondrial Adenosine 
15 
 
Tri Phosphate (ATP) production due to lipid accumulation in skeletal 
muscle which leads to impairment in mitochondrial oxidative 
phosphorylation. Reactive oxygen species are generated due to impaired 
fatty acid oxidation and lipid accumulation within skeletal myocytes. 
Increase in free fatty acids due to increased adipocyte mass, impairs 
glucose utilization in skeletal muscle, promotes hepatic gluconeogenesis 
and impairs beta cell function. Cytokines secreted by adipose tissue 
contributes to the rise in IL-6 and CRP in type 2 DM
29
. 
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Fig 3.2: Insulin signal transduction pathway in skeletal muscle 
 
 
 
Source: Dan Longo,Anthony Fauci,Dennis Kasper,Stephen Hauser. 
Harrison's Principles of Internal Medicine.18th edition .chapter 344, 
Diabetes mellitus: fig 344-5, 2972 
 
17 
 
 
Impaired insulin secretion: 
Variations in blood glucose concentration activate the beta-cells of 
the pancreatic islets to secrete insulin. In response to a rapid increase in 
blood glucose concentration, insulin is released from the beta-cells of 
pancreas in a biphasic pattern (fig 3.3).  The first phase in insulin 
secretion lasts only for few minutes followed by a slower and steadily 
evolving second phase, which lasts till the glucose level remains elevated. 
Conversely, a slow increase in plasma glucose level induces a 
progressively larger secretion without the first phase of insulin secretion. 
Type 2 diabetic patients has a substantially lower first phase of insulin 
secretion than the healthy subjects, and often it may be absent. The 
second phase of insulin secretion is also lower than healthy subjects
30
. 
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Fig 3.3: Phases of insulin secretion  
 
 
Modified from Lupi R, Del Prato S. Beta-cell apoptosis in Type II 
diabetes: quantitative and functional consequences. Diabetes Metab. 2008 
Feb; 34 Suppl 2:S56-S64 
 
By diffusion, glucose enters the pancreatic beta cells through 
GLUT2 transporters and stimulates them to secrete insulin. The 
pancreatic beta-cell metabolises glucose to produce ATP, and the increase 
in ATP/ADP ratio favours the closure of ATP-sensitive K
+
 channels in 
the cell surface which causes depolarization of the cell-membrane. As a 
result of depolarization, voltage-dependent Ca
2+
 channels are opened 
19 
 
facilitating the entry of extracellular Ca
2+
into the beta-cells. The rise in 
cytosolic Ca
2+
 inside the beta cells triggers the release of insulin
29
.  
Fig 3.4: Glucose mediated insulin secretion in beta cells of pancreas 
 
 
Source: Diva D De León and Charles A Stanley .Mechanisms of Disease: 
advances in diagnosis and treatment of hyperinsulinism in 
neonates.Nature Clinical Practice Endocrinology & Metabolism 2007; 
3:57-68 
20 
 
Elevated free fatty acids and chronic hyperglycemia also 
contributes to the worsening of islet function. Resistance to insulin action 
in adipose tissue leads to lipolysis and increased free fatty acids in turn 
leads to increased synthesis of very low density lipoprotein and 
triglyceride in hepatocytes. These changes are the reason for dyslipidemia 
in type 2 diabetes mellitus. The three main mechanisms leading to 
augmented beta-cell apoptosis are chronic hyperglycemia, lipotoxicity, 
and islets amyloid polypeptide (IAPP) deposition. Insulin secretion in 
type 2 diabetes is also affected by genetic variants through their effects on 
conversion of proinsulin, release of insulin on glucose stimulation, 
incretin secretion or sensitivity to incretin action, proliferation of beta 
cells and apoptosis
26
. 
 
Complications of diabetes mellitus
26
: 
Acute complications: 
Ketoacidosis  
                Hyperglycemic hyperosmolar nonketotic syndrome 
                Hypoglycemia 
 
21 
 
Chronic complications include  
• Microvascular 
            Eye disease 
                 Retinopathy (nonproliferative/proliferative) 
                 Macular edema 
           Neuropathy 
                 Sensory and motor (mono- and polyneuropathy) 
                 Autonomic 
                 Nephropathy 
• Macrovascular 
          Coronary artery disease 
          Peripheral arterial disease 
          Cerebrovascular disease 
• Others 
          Gastrointestinal dysfunction such as gastroparesis, diarrhea 
          Genitourinary abnormalities such as uropathy/sexual dysfunction 
22 
 
         Dermatological conditions 
         Infections 
         Cataract 
         Glaucoma 
         Periodontal disease 
 
Acute complications of DM: 
Diabetic Ketoacidosis (DKA): 
DKA is characterized by absolute lack of insulin with blood 
glucose levels usually >200 mg/dL, increased free fatty acid levels, 
increased production of ketone body, raised ketone body levels in blood 
and acidosis (pH ≤ 7.3).Patients with DKA presents with acute abdominal 
pain, kussmaul`s breathing, dehydration with signs and symptoms of 
hyperglycemia. In patients suffering from diabetes mellitus precipitating 
factors for DKA include the following 
 
• Bacterial and viral Infections  
• Acute illness 
• Lack of awareness on  diabetes education  
23 
 
• Non-compliance, reduced self-care 
• Inadequate monitoring of glucose 
• Psychiatric problems 
Morbidity and mortality associated with DKA depends on the 
severity of electrolyte and acid-base disturbances leading to coma and 
death
31
. 
 
Hyperosmolar non-ketotic coma: 
It is defined by the presence of hyperglycemia due to relative 
insulin deficiency with blood glucose level usually >1000 mg/dL with 
elevated serum osmolality >300 mosm/kg, signs of dehydration and 
stupor. If not corrected it may progress to coma with no evidence of 
ketosis or acidosis. This is because these patients have sufficient amount 
of insulin to prevent ketosis and lipolysis. The usual precipitating factors 
are medications such as corticosteroids, thiazide diuretics, dehydration, 
acute illness, infections,cerebral vascular disease and old age
32
. 
 
Hypoglycemia: 
Hypoglycemia commonly occurs in diabetic patients on treatment 
with insulin and it may also occur in diabetic patients treated with the oral 
hypoglycemic agents such as sulfonylureas. Hypoglycemia varies from 
blood glucose level of 60-70 mg/dL with minimal or no symptoms, to 
24 
 
severe hypoglycemia with blood glucose level of less than 40 mg/dL 
along with neurologic impairment. Oral carbohydrates are sufficient to 
manage glucose levels of 40-70 mg/dL and no other medical intervention 
is required whereas glucose levels less than 40 mg/dL requires further 
medical intervention with intravenous glucose or glucagon.  
 
Precipitating factors include  
• Drug dosage errors 
• Human insulin use 
• Secretion of  counter regulatory hormones can be impaired 
• Heavy Exercise 
• Skipping meals or delayed meals 
• Intensity at which  glycemic control is acheived 
• Absorption of insulin from subcutaneous depots may vary 
• Insulin binding to receptors, insulin action, rate of degradation may 
vary 
Renal, adrenal and pituitary insufficiency contributes to the increased 
frequency of hypoglycemic events in diabetic patients
33
. 
 
 
 
25 
 
Chronic complications of DM 
34
: 
 
Diabetes mellitus being a chronic disease affects multiple organs 
and they contribute to majority of morbidity and mortality in these 
patients.  
 
Chronic complications are of two types  
• Vascular 
• Nonvascular  
 
The vascular complications are further divided into  
• Microvascular  which include retinopathy, neuropathy, and 
nephropathy 
• Macrovascular complications which include coronary artery 
disease, peripheral vascular disease, cerebrovascular disease.  
 
Diabetic retinopathy: 
It is the most frequently occurring microvascular complication and 
its occurrence depends on the duration and severity of diabetes mellitus. 
Increase in blood glucose levels increases the entry of sugar molecules 
through the polyol pathway, which converts glucose to sorbitol leading to 
its accumulation within the cells. Sorbitol accumulation within the cells 
causes osmotic stress which is believed to be the cause for basement 
26 
 
membranes thickening, microaneurysm formation and pericyte loss. 
Growth hormone, vascular endothelial growth factor (VEGF) and 
transforming growth factor β, have also been known to play important 
roles in the progression of diabetic retinopathy
34
. 
 
Diabetic nephropathy: 
 Diabetic nephropathy is one of the important causes of renal 
failure. Microalbuminuria is a condition where albumin excretion is 
between 30-299 mg/day. Microalbuminuria in diabetic patients if not 
treated may progress to massive proteinuria and then leading to diabetic 
nephropathy. Similar to diabetic retinopathy, there is a strong association 
between glycemic control and the risk of developing diabetic 
nephropathy. The pathological changes in the kidney include increase in 
the thickness of glomerular basement membrane, formation of 
microaneurysms and mesangial nodules called as Kimmelsteil-Wilson 
bodies. Albuminuria occurring in patients with type 2 diabetes mellitus 
may also be due to other diseases like hypertension, congestive heart 
failure, prostate disease and infection
34
. 
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Diabetic neuropathy: 
Diabetic neuropathy presents with signs and symptoms of 
peripheral nerve dysfunction in people with diabetes after other causes 
have been excluded. Development of diabetic neuropathy also depends on 
the duration and severity of diabetes mellitus. Neuropathy in diabetics 
manifests as polyneuropathy , mononeuropathy,  and/or autonomic 
neuropathy. Chronic distal symmetric sensorimotor polyneuropathy is the 
most frequent form of neuropathy in diabetes
34
. 
 
Pathogenesis of microvascular complications: 
Microvascular disease occurs predominantly in tissues where 
uptake of glucose is not dependent on insulin activity such as retina, 
vascular endothelium and renal cells. These insulin independent tissues 
are continuously exposed to increased glucose levels in diabetic patients. 
Glucose-mediated endothelial damage, overproduction of superoxides 
leading to oxidative stress, production of sorbitol and advanced glycation 
end-products due to hyperglycaemic state (fig 3.5) contributes to the 
development of microvascular disease. These metabolic insults alter the 
rate of blood flow and causes change in endothelial permeability, 
deposition of extravascular protein and coagulation abnormalities ensuing 
organ dysfunction. 
28 
 
Fig 3.5: Pathobiology of diabetic complications  
 
 
 
Source: Michael Brownlee. Biochemistry and molecular cell biology of 
diabetic complications. Nature 2001; 414: 813-820 
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Macrovascular complications of Diabetes: 
The socio economic burden of diabetes mellitus is mainly 
attributed to its macrovascular complications. The basic pathology behind 
the occurrence of macrovascular disease is atherosclerosis.  
 
Atherosclerosis, a multifactorial disease is characterized by 
cholesterol accumulation, infiltration of macrophages, smooth muscle cell 
proliferation, accumulation of connective tissue components and 
thrombus formation. 
 
Pathogenesis of atherosclerosis: 
Atherosclerotic lesions develop under an intact endothelium but 
when the integrity of the endothelium is altered. Proteins and lipoprotein 
particles extravasate through the defective endothelium into the 
subendothelial space. 
 
 Atherogenic modification of Low Density Lipoprotein (LDL) is 
mediated by myeloperoxidase, 15-lipoxygenase and nitric oxide synthase 
(NOS). This modified LDL is pro-inflammatory, chemotaxic and 
proatherogenic.  Nitric oxide produced by inducible NOS in 
macrophages, is potentially proatherogenic. Atherogenic stimuli such as 
elevated cholesterol, smoking and proinflammatory stimuli activates the 
endothelium and upregulates  the expression of adhesion molecules 
30 
 
primarily vascular cell adhesion molecule-1(VCAM-1), followed by 
recruitment of monocytes and T cells. In addition to VCAM-1, other 
adhesion molecules, such as intercellular adhesion molecule-1, E selectin, 
and P selectin also have a say in the recruitment of blood cells to the 
atherosclerotic site. 
 
 The first cellular responses to occur in atherogenesis are the focal 
recruitment of circulating monocytes followed by T lymphocytes to a 
lesser extent. There is an increase in Monocyte chemotactic protein-1, a 
powerful chemokine and its receptor on monocytes and macrophages 
during plaque development and is necessary for trans-endothelial 
migration of cells. Macrophages, endothelial cells and smooth muscle 
cells contribute to the over expression of this chemokine in the process of 
atherosclerosis. Foam cells are the hallmark of atherosclerotic lesions. 
Lipid-laden macrophages containing cholesteryl esters in abundance are 
called foam cells. Apoptosis and necrosis of macrophages contributes to 
the formation of a lipid-rich necrotic core which is soft and destabilizing 
within the atherosclerotic plaque. Smooth muscle cells and the collagen 
enriched matrix retrieves stability to plaques thereby protecting them 
from plaque rupture and thrombosis
35
. 
 
 
31 
 
Endothelial injury plays a pivotal role in the pathogenesis of 
atherosclerosis. A plethora of factors such as excessive smoking, rise in 
cholesterol levels, chronic diseases like diabetes, hypertension, excessive 
physical activity and resistance to blood flow in the arteries initiates 
atherosclerosis by promoting endothelial dysfunction. These factors serve 
as stimuli for low density lipoprotein accumulation in the arterial vessels. 
ROS generated by a diversity of extracellular and intra-cellular 
mechanisms leads to oxidation of LDL. 
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Fig3.6: Pathogenesis of atherosclerosis  
 
 
 
Source: Robbins textbook of basic pathology 8 
th 
edition chapter 11 blood 
vessels,fig 11-9, page 499 
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Fig 3.7: Schematic representation of the involvement of oxidized 
LDL, endothelial cell injury and vascular smooth muscle cell 
proliferation in the development of Atherosclerotic plaque. 
 
 
Source: Singh RB, Mengi SA, Y-J Xu, Arneja AS, Dhalla NS. 
Pathogenesis of atherosclerosis: A multifactorial process. 
Exp Clin Cardiol 2002; 7(1):40-53. 
  
34 
 
Oxidized LDL accelerates the recruitment and withholding of 
monocytes and macrophages. It also promotes the synthesis of cytokines 
and various other growth factors. They bind to scavenger receptor and 
activate endothelial cells, smooth muscle cells and monocytes. Oxidized 
LDL also mediate vasoconstriction, formation of thrombus and 
aggregation of platelets through the activation of protein kinases present 
inside the cell and transcription factors like NFκB. Oxidized LDL also 
stimulates the expression of cellular adhesion molecules on endothelial 
cells, macrophages and monocytes . It stimulates the  production of  
various cytokines and growth factors in vascular smooth muscle cells for 
example monocyte chemoattractant protein-1, platelet-derived growth 
factor and procoagulant factors such as plasminogen activator inhibitor-I. 
Oxidized LDL produces vasoconstriction by decreasing the formation of 
the vasodilators such as nitric oxide and prostaglandin by the endothelium 
which enhances the synthesis of the vasoconstrictor endothelin-1. The 
uptake of oxidized LDL by monocyte-derived macrophages slows down 
macrophage migration in the subendothelial space and leads to the 
formation of foam cells which are the hallmark of atherosclerotic 
lesions
35
.  
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Diabetes mellitus and cardiovascular disease: 
Diabetes increases the risk of cardiovascular disease  and coronary 
artery disease and is said to be the cause for about 75% of deaths in 
diabetics 
36
. Incidence rate of myocardial infarction in diabetic 
individuals was similar to the incidence rate in non-diabetic individuals 
who had previous history of myocardial infarction. Recent studies have 
concluded that increased levels of C-reactive protein, fibrinogen and 
leukocytosis are the other risk factors for cardiovascular disease (CVD) in 
diabetic individuals 
37
. 
 
Cardiovascular diseases are the most common cause of morbidity 
and mortality in people with type 2 diabetes mellitus
38
. Diabetes, a 
chronic disease is considered to be a state of low grade inflammation and 
immune activation leads to insulin resistance in pre-diabetic and diabetic 
individuals. This eventually increases the risk for cardiovascular 
diseases
39
. Patients with diabetes mellitus aggravate other co-morbidities 
like hypertension, obesity and altered lipid profile which in turn increase 
the risk for Cardio Vascular Disease 
40
. National Cholesterol Education 
Program considers diabetes mellitus to be a risk factor for coronary heart 
disease 
41
. 
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Fig 3.8: Diabetes and Endothelial dysfunction 
 
GTPCH: GTP cyclohydrolase; BH4: tetrahydrobiopterin;                        
BH2: dihydrobiopterin. 
Source: Gopi Krishna Kolluru et al. Endothelial Dysfunction and 
Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound 
Healing. International Journal of Vascular Medicine.Volume 2012, 
Article ID 918267 
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Glycemic control and CVD: 
There were numerous studies depicting the significance of 
glycemic control in patients with diabetes and cardiovascular disease. The 
United Kingdom Prospective Diabetes Study (UKPDS), have shown that 
early intensive treatment of hyperglycemia in newly diagnosed Type 2   
DM patients in the first five years of disease protects against 
cardiovascular diseases, when compared to patients in the conventional 
treatment group
42
.  
              Veterans Affairs Diabetes Trial (VADT) was done in elderly 
diabetic patients. Mean duration of the disease in these patients was 10 
years. When subjected to an intensive glycemic control, they had no 
protection against cardiovascular diseases. 40% of patients included in 
this study had previous history of cardiovascular disease
43
. 
             Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
trial was done with the aim of  reducing HbA1c below 6% in Type 2 DM 
patient .According to this study intensive glycemic control had no effect 
on  reducing cardiovascular events instead it increases body mass 
index,risk of hypoglycemia and also increases mortality
44
.  
                 Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation (ADVANCE) trial 
38 
 
was done with the aim of reducing HbA1c to 6.5% by treating them with 
oral hypoglycemic agents like gliclazide and other drugs. Similar to 
ACCORD trial,this study also had no effect on  reducing cardiovascular 
events . But the incidence of diabetic nephropathy was reduced
45
.  
             DCCT study showed findings quite different from ACCORD, 
ADVANCE trial. DCCT study was done in patients with short duration of 
diabetes who had no cardiovascular risks. The early initiation of 
treatment in these patients to reduce the HbA1c levels below 7% lowers 
the incidence of cardiovascular diseases. But this does not hold good for 
older patients with persistently high blood sugar and with increased risk 
for cardiovascular events
46
. This early protection is due to metabolic 
memory. Metabolic memory has a long term protective effect on target 
organs in later years due to intensive blood glucose control achieved in 
early years. The mechanisms behind metabolic memory appear to be due 
to oxidative imbalance, low level inflammation and endothelial 
dysfunction resulting from epigenetic and metabolic changes inside the 
cell
 47
. 
                  German Diabetes Intervention Study was done in newly 
diagnosed type 2 diabetic patients. According to this study controlling 
post-prandial hyperglycemia in newly diagnosed patients had much more 
39 
 
benefit in reducing the incidence of CVD and overall mortality rather 
than controlling fasting blood glucose
48
. 
 
Role of inflammation in diabetes mellitus: 
Inflammation is a short term protective tissue response elicited by 
the body to deal with injuries and microbial infections. Inflammation can 
be eminent in chronic diseases such as diabetes mellitus, chronic kidney 
disease and liver diseases. Abnormal levels of chemokines released by 
the expanding adipose tissue in obese individuals stimulates monocytes 
and thereby increases the synthesis of pro-inflammatory cytokines like 
interleukin 6,interleukin 1 β  and tumor necrosis factor (TNF)-α. The 
secreted cytokines down regulate most important anabolic pathways 
concerned with insulin signaling and also mediates  insulin resistance in 
peripheral tissues thus increasing  the risk for Type 2DM. Apart from 
their effect on insulin resistance, they also exert an influence on 
hepatocytes and upregulates the synthesis  of very-low density 
lipoproteins (VLDL), resulting in dyslipidemia. They also increase the 
synthesis of fibrinogen, an atherosclerotic risk factor secreted by the liver 
cells. Cytokines blocks the activation of the liver X receptors (LXR), 
leading to cholesterol accumulation which ultimately triggers the 
synthesis and secretion of acute-phase reactants like C-reactive protein 
(CRP), plasminogen activator inhibitor-1 (PAI-1), serum amyloid-A, α1-
40 
 
acid glycoprotein, and haptoglobin  by hepatocytes. These are together 
referred to as inflammatory markers. Acute-phase reactants characterize 
the early stages of Type 2DM and their levels increase with the 
progression of disease and development of complications
49
. 
 
hsCRP- predictor of  cardio vascular disease: 
 
Nearly half of all myocardial infarction and stroke occurs without 
elevated cholesterol levels. So there is a need for a marker which has a 
critical role in inflammation and atherothrombosis. C-reactive protein is a 
multi-complex protein whose level increases when there are instances of 
inflammation in the body. CRP being an acute phase reactant may rise in 
infection and trauma also. Though it is an acute phase protein CRP is 
biologically stable over a longer period of time
50
. But studies have shown 
CRP, when measured with high-sensitivity assays appropriately in steady 
individuals, is more specific for predicting future cardiovascular events
51
.  
 
        One of the previous studies has shown that highest quartile of  
hsCRP had two times the risk of future stroke (51.9 -Relative Risk; 95%  
Confidence Interval,1.1–3.3), thrice  the risk of future myocardial 
infarction (52.9-Relative Risk; 95% Confidence Interval, 1.8–4.6) and the 
risk of future peripheral vascular disease is increased  four times (54.1-
Relative Risk; 95% Confidence Interval, 1.2–6.0)
52
.Numerous studies 
41 
 
indicate that the relationship between hsCRP and future cardiovascular 
risk are largely independent of cholesterol and other risk factors
53, 54, 55
.  
 
         The CDC-AHA“Workshop on Inflammatory Markers and 
Cardiovascular Disease: Application to Clinical and Public Health 
Practice” suggests that apart from all other markers of inflammation such 
as serum amyloid A, leukocyte count and fibrinogen , hs-CRP levels are 
more stable with high assay precision, accuracy and accessibility.                                          
American Heart association has set hsCRP cut points to be < 1 mg/L, 1 to 
3 mg/L, and > 3mg/L which corresponds to low-risk, medium-risk, and 
high risk groups respectively. CRP levels serves as a prognostic marker 
when used along with LDL cholesterol level or Framingham risk score
56
. 
Type 2 diabetes patients with acute coronary syndrome, CRP serves as an 
independent marker for predicting cardiovascular death
57
. 
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Fig 3.9: Framingham risk score for prediction of cardiovascular 
events based on hsCRP values 
 
 
 
Source: Ridker PM et al: Comparison of C-reactive protein and low-
density lipoprotein cholesterol levels in the prediction of first 
cardiovascular events. N Engl J Med 2002;347:1557 
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Clinically hsCRP estimation should not be done when there is 
evidence of infection or trauma recently
50
. hsCRP measurement  gives 
prognostic information at every level of metabolic syndrome
58
. 
hsCRP enhances atherosclerosis by the following mechanisms 
59, 60
. 
 
• Activates complement cascade 
• Expression of adhesion molecules like E-selectin and vascular cell 
adhesion molecule-1 is induced 
• Expression and action of plasminogen activator inhibitor-1 in 
     Human endothelial cells is increased 
• T-cell-mediated endothelial cell destruction is enhanced 
• Entry of LDL particles into macrophages is also enhanced 
 
Oxidative stress in diabetes mellitus: 
 
Oxidative stress occurs either due to increased synthesis of reactive 
oxidizing species or a marked reduction in the efficiency of antioxidant 
defense mechanism
61
. Oxidative damage to biological molecules like 
proteins, lipids, carbohydrates and nucleic acids has been concerned in 
the pathogenesis of many chronic diseases like diabetes mellitus, 
cardiovascular diseases and cancer. 
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        Reactive Oxygen Species (ROS) comprises of a large number of 
reactive molecules and free radicals formed from molecular oxygen. ROS 
are synthesized as byproducts when electrons are transported in 
mitochondria during aerobic respiration. They may also be produced by 
oxidoreductase enzymes and during metal catalyzed oxidation reactions. 
ROS are necessary for maintaining redox potential for normal cell 
growth, gene expression and the activation of cell signaling pathways 
including apoptosis. But at high concentration ROS are able to cause 
oxidative damage
62
. 
         Radical is any atom or molecule with an unpaired electron in its 
outermost shell which makes it extremely reactive. The two unpaired 
electrons in the outermost electron shell of atomic oxygen in separate 
orbitals make it susceptible to radical formation. The antibonding orbitals 
of oxygen have the capacity to accept electrons which undergoes 
reduction during the process and thus enabling it to act as a strong 
oxidizing agent. Addition of electrons to oxygen sequentially results in 
the production of numerous ROS. The various ROS generated are 
superoxide radicals, H2O2, nitric oxide derivatives, hydroxyl radical and 
ion. Cells have a plethora of mechanisms to protect against the 
deleterious effects of ROS
63
. 
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         Addition of one electron to oxygen leads to the formation of 
superoxide anion O2 
−
·.Although a weak oxidizing agent O2 
−
· serves as a 
source for the production of strong oxidising agents. O2 
−
· in aqueous 
solution is short-lived due to the rapid dismutation of superoxide anion to 
hydrogen peroxide and O2.  Though H2O2 is not a radical it has the ability 
to be formed by reduction of Oxygen by two electrons. This reaction 
sequence is common to a number of flavoprotein oxidases
64
. Hydrogen 
peroxide is a weaker oxidizing agent than O2 
−
· Unlike O2 
−
·, H2O2 freely 
diffuses across biological membrane and is more stable than superoxide 
anion. H2O2 in the presence of transition metals such as iron, copper 
forms the hydroxyl radical (OH·) which is highly reactive and the 
hydroxide ion
65
. 
        The hydroxyl radical being very reactive removes electrons from 
any molecule along its path thereby converting it into a free radical. This 
initiates a chain of reactions by the free radicals. Lipids in cell membrane 
are more prone to damage by these radical chain reactions
63
.It can also 
start lipid peroxidation by taking an electron from polyunsaturated fatty 
acids.H2O2 is converted to hypochlorous acid (HOCl) in the presence of 
chloride ion. HOCl is highly oxidative and plays an important role in 
killing pathogens in airways .Moreover it also induces DNA–protein 
interactions and produce pyrimidine oxidation products and add chloride 
46 
 
to DNA bases
66
.Peroxyl radical (ROO
.
) initiates a chain reaction and 
transforms polyunsaturated fatty acids into lipid hydroperoxides which  
are unstable and easily decompose to secondary products,such as 
aldehydes such as 4-hydroxy-2,3-nonenal and malondialdehydes 
(MDAs).Lipid peroxidation disturbs the integrity of the cell membrane
67
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 3.10: Mechanisms of cellular oxidative damage 
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Sources of ROS 
There are two major sources of ROS namely enzymatic and 
nonenzymatic sources. Among the sources,under reducing conditions  
mitochondria accounts for 1–2% of total Oxygen consumption. 
Superoxide dismutase (SOD) when present in high concentration 
maintain the superoxide ion levels inside the mitochondria at a very low 
and steady level. Mitochondria also functions as an Oxygen sensor to 
mediate hypoxia-induced gene transcription. Apoptosis induced by tumor 
necrosis factor (TNF)-α and interleukin (IL)-1 involves ROS derived 
from mitochondria. Endoplasmic reticulum derived oxidants and growth 
factor signaling regulates protein folding and secretion.  
 
       Electrons leaking from electron transport systems generate ROS 
which has the ability to damage cellular DNA. Glycolate oxidase, D-
amino acid oxidase, urate oxidase, L-alpha-hydroxyacid oxidase and 
peroxisomal fatty acyl-CoA oxidase are the major source of total cellular 
H2O2 production. In addition to oxidases present in the membrane of the 
cell, enzymes like xanthine oxidase, aldehyde oxidase, dihydroorotate 
dehydrogenase, flavoprotein dehydrogenase and tryptophan dioxygenase 
are also capable of generating ROS during catalytic process.  
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Dopamine, epinephrine, flavins and hydroquinones on auto-
oxidation form the major source of ROS production within the cell
 65, 68
.
 
Phagocytic cells on stimulation produce ROS. This was referred to as 
respiratory burst which is due to the increased utilization of oxygen by 
these cells. This reaction is mediated by the multicomponent enzyme 
which is   membrane bound namely NADPH oxidase. 
 
Antioxidants: 
Antioxidants are substances that have the ability to deactivate and 
scavenge the free radicals before they induce cell damage. They are 
necessary for maintaining normal cell growth and well-being. 
 
Antioxidants can be derived from nutrient sources. They  include 
water soluble vitamin such as vitamin C, fat soluble vitamin such as  
vitamin E  and its derivatives (tocopherols and tocotrienols), precursors 
of vitamin A (carotenoids) and other compounds such as glutathione and 
lipoic acid. The antioxidant effect of vitamin C begins before the 
initiation of lipid peroxidation. Fatty acids present in membranes are 
protected from lipid peroxidation by vitamin E. Beta carotene and other 
carotenoids work synergistically with vitamin E and protect lipid-rich 
tissues
69
.  
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        Lipoic acid functions as universal antioxidant by quenching free 
radicals in both lipid and aqueous domains
70
. Antioxidant enzymes like 
superoxide dismutase, glutathione peroxidase and catalase are called as 
primary antioxidant enzymes. Superoxide dismutase catalyzes the 
conversion of two superoxide anion to form Hydrogen peroxide and 
molecular oxygen. In this reaction one O2 
−
 is oxidized to form molecular 
oxygen and the other O2 
−
 is reduced to form H2O2.Glutathione 
peroxidase catalyses the reduction of H2O2 to water which requires two 
reduced glutathione molecules (GSH). GSH is a tripeptide containing 
amino acids cysteine, glutamic acid and glycine. Moreover sulfhydryl 
groups such as thiol and small tripeptide glutathione act as non enzymatic 
low molecular weight antioxidants
71
.  
 
Oxidative stress in DM: 
Increased glucose levels leads to increased production of 
superoxide radicals by mitochondria. These radicals bring about DNA 
damage which increases the activity of poly-ADP-ribose polymerase-1 
(PARP-1). This enzyme plays a major role in DNA repair mechanisms 
and pathways related to apoptosis. PARP-1 activation results in inhibition 
of glyderaldehyde-3-phosphate dehydrogenase (GAPDH), an enzyme 
involved in glycolysis by poly-ADP-ribosylation. This leads to an 
increase in the intermediates of glycolytic pathway upstream of GAPDH. 
51 
 
As a result, two major pathways related to diabetic complications namely 
advanced glycation end product pathway (AGE) and diacyl glycerol- 
protein kinase C (DAG-PKC) pathway are activated. Activation of the 
AGE pathway results in nonenzymatic synthesis of methylglyoxal. 
Increase in fructose 6-phosphate increases the flux through the 
hexosamine pathway and leads to a rise in blood glucose levels. The 
increase in glucose is shunted through the polyol pathway, where 
NADPH is consumed. As a result glucose is reduced to sorbitol by aldose 
reductase. Synthesis of reduced glutathione, a powerful antioxidant 
requires the cofactor,NADPH .Depletion of NADPH, modifies the redox 
state of the cells exacerbating intracellular oxidative stress by scavenging 
ROS. Further, sorbitol on oxidation forms fructose by the action of the 
enzyme sorbitol dehydrogenase. The resulting increase in NADH/NAD+ 
ratio activates protein kinase C pathway.      
 
When there is a rise in intracellular glucose level, excess fructose-
6-phosphate is transformed to UDP-N Acetylglucosamine, which plays a 
essential role in the production of carbohydrate chains of proteins and 
lipids. UDP-N Acetylglucosamine is also needed for the post-
translational modification of proteins present in the cytoplasm and 
nucleus in serine and threonine residuesre. Increase in dihydroxyacetone 
phosphate in hyperglycemic environment leads to increased denovo 
52 
 
synthesis of DAG which activates protein kinase C isoforms. PKC 
isoforms stimulates a large range of cellular signals that activates 
NADPH oxidase and nuclear factor -κB leading to disproportionate 
reactive oxygen species production.  
 
Apart from the activation of AGE production and the PKC 
pathway, glyceraldehyde 3-phosphate can undergo autooxidation 
generating H2O2 which further contributes to oxidative stress
72
. 
  
The glucotoxicity in diabetic patients leads to the formation of 
intracellular and extracellular AGEs. Glucose undergoes auto-oxidation 
to glyoxal. Amadori product on decomposition forms 3-deoxyglucosone. 
Methylglyoxal  is formed by  nonenzymatic phosphate elimination from 
glyceraldehyde phosphate and dihydroxyacetone phosphate which on  
reacting with amino groups of intracellular and extracellular proteins 
forms AGE products. The mechanisms by which AGE precursors causes 
cell damage are by altering the function of intracellular 
proteins,modification of  extracellular matrix components. These 
modified proteins bind to AGE receptors on macrophages, monocytes, 
endothelial and smooth muscle cells present on the vessels and induce the 
formation of ROS, leading to the activation of   PKC
72
.  
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These highly reactive oxygen species have the capacity to alter the 
function of nucleic acids and cause cell damage by modifying 
carbohydrates, proteins and lipids.  
 
Protein thiols, marker of oxidative stress: 
Thiols are organosulfur compounds containing alcohol as a 
functional group. They encompasses the sulfhydryl groups and 
disulphides present on proteins with homocysteine,glycine, 
cysteinylglycine and glutathione. They are the major antioxidants in the 
body in defense against reactive oxygen species. Oxidation of thiols can 
lead to the formation of intra molecular disulfides, intermolecular mixed 
disulfides, mixed disulfides formed between protein thiols and 
GSH
73
.The sulfhydryl group present in cysteine is essential for the normal 
biological activity of glutathione. Oxidation of thiols can also result in 
damage to proteins with severe functional consequences.  
 
There are two major proposed mechanisms for redox signaling.  
 One is based on thermodynamic principles which states that all thiols and 
disulfides exist in equilibrium with each other.GSH is a redox buffer and 
exists in its oxidised or reduced form based on the redox potential of the 
cell.  
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     The other mechanism is based on the kinetic properties of specific and 
sensitive targets. According to this mechanism, nearly all physiological 
oxidants react with thiols although most show selectivity for thiolate 
anion by causing one electron or two electron oxidations. The one 
electron oxidation forms a thiyl radical, which undergoes further 
reactions including transfer of radicals to the antioxidant ascorbate. The 
thiyl radical preferentially reacts with a thiolate anion from a protein or 
glutathione to form the disulfide anion radical. The two electron 
oxidation of thiols initially produces a series of intermadiates like sulfenic 
acid, sulfonamide, sulfonamide, sulfenylamide, mixed disulfides, inter 
and intra molecular disulfides (fig 3.10) 
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Fig 3.11: The one and two electron oxidations of protein thiols 
 
 
 
 
Adapted from Winterbourn CC, Hampton MB. Thiol chemistry and 
specificity in redox signaling Free Radic Biol Med. 2008 Sep 1; 
45(5):549-61. 
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Almost all physiologically relevant oxidants are capable of reacting 
with thiols. H2O2 reacts directly with thiolate anions, following the two 
electron oxidation path. Radical oxidation reactions can produce thiyl and 
sulfinyl radicals during the process of a radical chain reaction. Other 
common thiol oxidants like peroxynitrite, can react directly with thiols or 
break down into the reactive hydroxyl radical, nitrogen dioxide and 
hypohalous acids. Thus the cells respond to oxidative stress by altering 
the redox state of critical thiols
74
.In human plasma protein sulfhydryl 
groups is in the concentration of 0.4–0.5 mM , where as low-molecular 
mass thiols is in the concentration of 0.1–20 µM 
75
. Albumin being the 
most abundant protein in plasma, total thiol level in the body depends on 
the amount of thiol groups present on albumin.  
 
Thiol groups present on amino acids like cysteine stabilize protein 
structures by forming covalent disulfide bonds and by their high 
reactivity and redox properties
76
. Modification of thiol groups results in 
the formation of mixed and internal disulfides, thiyl radicals, sulfinic and 
sulfonic acids. Protein sulfhydryls on oxidation forms  mixed disulfides   
( protein S thiolation) and on reduction once again forms sulfhydryls 
(dethiolation) .This is considered to be the early cellular response against 
oxidative stress
73
.Protein thiols have the ability to scavenge two third of 
the total reactive species generated in the body. Thus the level of protein 
57 
 
thiols in the serum indicates the antioxidant level in the body. Increase in 
lipid peroxidation and protein oxidation causes a fall in protein thiol 
levels in the serum
77
.  
 
    Glutathione and thioredoxin are thiol buffers present inside the cell. 
The balance between the levels of these intracellular thiol buffers and the 
reactive oxygen species determines the redox state of the cell. When there 
is a remarkable rise in reactive oxygen species than that of the 
compensatory endogenous thiol buffers, there is a persistent activation of 
genes and signaling pathways that stimulates apoptosis in the affected 
cells. Glutathione comprising of   glycine, glutamic acid and cysteine is 
the most common nonprotein sulfhydryl compound and this forms the 
majority of endogenous thiol buffers in the cell
78
. 
 
       Serum protein thiol levels are decreased in both type 1 and type 2 
diabetes mellitus. This decrease was expounded to some extent by 
metabolic, inflammatory and iron alterations
79
. Serum protein thiols are 
also decreased in type 2 diabetes mellitus patients with complications
80
. 
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4. Materials and Methods: 
This study was conducted in the department of Biochemistry, PSG 
IMS&R during the period of june 2013 to june 2014 with the approval of 
institutional human ethics committee. 
It is a cross sectional study including two groups: 
Group 1: Type 2 diabetes mellitus patients without complications 
Group 2: Type 2 diabetes mellitus patients with cardiac complications 
Study was initiated after obtaining informed consent from the participants 
of the study. 
Inclusion criteria: 
For groups 1 & 2 
 Age 30-75 years 
 Males and females included 
 Duration of diabetes: a minimum period of 6 months from the date 
of diagnosis 
 
For group 1  
 Type 2 Diabetic patients reporting to Endocrinology department  
and on treatment with Antidiabetic drugs  
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For group 2 
 Type 2 Diabetic patients reporting to the department of Cardiology 
with cardiac complications and on treatment for the same 
 
Exclusion criteria: 
           Subjects (all groups) 
 
 With Hypertension 
 With acute inflammatory diseases (trauma, viral and bacterial 
infections) 
 With chronic inflammatory diseases (Rheumatoid arthritis, 
Systemic lupus erythematosus, Bronchial asthma, Tuberculosis, 
Sarcoidosis and any chronic granulomatous diseases) 
 With malignant neoplasms 
 With Creatinine clearance less than 15 ml/min/End Stage Renal 
Disease /Stage V of Chronic Kidney Disease. 
 With visual defects and/or motor/sensory defects 
 Subjects on treatment for the above mentioned conditions 
 Subjects on hormone replacement therapy 
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Sample collection: 
5 ml of random venous blood sample was collected in EDTA and 
heparin tubes. HbA1c, Protein thiol levels were analysed on the day of 
collection. Samples for hsCRP analysis were stored at -23˚c    and were 
estimated collectively. 
Assay of plasma protein thiols: 
Method: Dinitrobenzene (DTNB)-Ellman’s method using 
sphectophotometry
81, 82 
Principle: 
  5, 5’-dithiobis (2-nitrobenzoate) [DTNB] is a symmetrical aryl 
disulfide which in the presence of a free thiol group readily undergoes the 
thiol-disulfide interchange reaction. The TNB di-anion absorbs light 
intensively at 412nm than that of both disulfides. Since the stoichiometry 
of protein thiol to TNB synthesized is 1:1, number of thiol groups present 
can be assessed by the number of TNB formed. When denaturants are not 
present, only accessible thiols can react.The total number of reduced 
cysteine residues present can only be measured in the presence of 
chaotropic agents.  Reduction of the protein followed by treatment with 
chaotropes and DTNB can only give the total number of cysteines (Cys-
SH plus Cys-S-S-Cys). The total plasma protein thiol concentration was 
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measured using the molar extinction coefficient of TNB complex 
(13,600/M/cm) in the assay mixture at 412 nm. 
 
 
 
 
Reagents: 
1.  Buffer: 0.2 M Na2 HPO4 containing 2 mM Na2 –EDTA, pH: 7.4: 
      0.2M Na2 HPO4 (MW: 142):  
     2.84 gm of Na2 HPO4 dissolved in 90 ml of Distilled water and made    
     upto 100 ml with distilled water. Stored in amber color bottle at 4
o
C. 
 
 
 
Mixed disulfide 
TNB 
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Working Buffer: 
Dissolve 74.4 mg of Na2 –EDTA (MW: 372.24) in 90 ml of 0.2 M 
Na2 HPO4 and made upto100 ml with 0.2 M Na2 HPO4.Prepared fresh 
before assay. 
 
2. Phosphate Buffer saline (PBS) pH: 7.4: 
 0.9  gram of sodium chloride. 
           0.2302 gram of Disodium Hydrogen Phosphate (Na2HPO4) 
           0.0194 grams of Sodium Dihydrogen Phostphate (NaH2PO4); 
All the above ingredients are dissolved separately in 80ml of 
distilled water. Mixed and then volume is made upto 100 ml with distilled 
water. Stored at room temperature. 
 
3. 10mM of 5, 5’-Dithio-bis-(2-nitrobenzoic acid) in 0.2 Na2HPO4             
(MW: 396.35): 
Prepare 39.63 mg/10 ml in 0.2M Na2 HPO4.Store in amber color bottle at 
4
o
C. It is stable for 4 weeks if stored in dark bottles.  
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Test Procedure: 
Dilution of plasma: 1:3; 100µl Plasma + 200 µl PBS.  
PBS, DTNB, 0.2 M Na2 HPO4 in 2 mM EDTA were pre-incubated at 
37
o
C before the assay. Three Eppendorf tubes were labeled as Reagent 
Blank (RB), Test (T) and Sample Blank (SB).Pipetting was done as 
mentioned below:    
  
REAGENT 
Reagent  
Blank 
Sample  
Blank 
Test 
0.2M,Na2HPO4 
Containing 2mMEDTA, (µL) 
900 920 900 
PBS (µL) 100 - - 
10mM DTNB(µL) 20 - 20 
Sample (µL) - 100 100 
 
The contents in each of the tubes were mixed in a Vortex, incubated 5min 
at room temperature. 
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  2 min gap was left between Reagent Blank and Test and each was 
read after 5min. 
 The solution was shifted to a cuvette and absorbance was estimated 
at 412 nm. 
 The reaction takes about 5 minutes to go to completion, during 
which there was an increase in the absorbance. The maximum 
value was recorded.  
 The sample blank was measured as bilirubin, beta carotene and 
other plasma constituents that absorb at 412 nm can interfere with 
protein thiol measurement 
 
Calculations: 
The absorbances for sample and reagent blanks were subtracted 
from test absorbance values to obtain the correct values. 
X= T-(SB+RB) = Abs. at 412nm 
 Applying the molar extinction coefficient, absorbance at 412 nm 
was divided by 13,600/M/cm to get the molarity in the assay 
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Thiol concentration  
µM/L        =          (Tot.vol/sample.vol)X  dilution factor X Abs at412 nm 
                                                       13600 
                 = 10.2 x 3 x Abs. at 412nm / 13600 M/L. 
                 = 0.00225 x Abs. at 412 nm x 10
6
 µMol/L. 
                 = 2250 x Abs. at 412 nm, µMol/L 
Linearity of the assay: 
As per the literature, the linear range of the procedure is 35-1200 
µMol in plasma with a coefficient of variation being 2.1%. 
Assay of high sensitivity C reactive protein: 
Method: Particle enhanced turbidimetric assay
83 
Principle: 
Human C reactive protein agglutinates with monoclonal anti-CRP 
antibodies coated on latex particles. The precipitate is measured 
turbidimetrically at 552 nm 
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Sample: plasma.  
Samples should be collected in Li- heparin containing tubes  
 
Reagents: 
Reagent 1:  Bovine serum albumin and immunoglobulins (mouse) in 
TRIS buffer 
Reagent 2= Standard Reagent: Glycine buffer with latex particles coated 
with anti CRP (mouse)  
Test definition: 
Mode of Measurement  Absorbance 
Mode of Abs. calculation  Kinetic 
Direction of reaction  Increase 
Wavelength A/B 552nm 
range of measurement  0.1-20 
Unit of measurement mg/L 
 
In normal adults normal reference limit is < 5 mg/ L  
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For risk stratification  
 
hsCRP value Risk  
< 1 mg/L Low risk 
1 to 3 mg/L Medium risk 
> 3mg/L High risk 
 
 
Pipetting parameters: 
 
REAGENT Volume Diluents (H2O) 
Reagent 1 82 µL 48 µL 
Sample 6 µL - 
Reagent 2 28 µL 14 µL 
Total volume 178 µL - 
 
Measured with cobas 400 autoanalyser 
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Assay of Glycated haemoglobin: (HbA1c) 
 
Method: Turbidimetric inhibition immunoassay
84
  
 
Principle: 
 
EDTA tube collected whole blood specimen is hemolysed after 
collection. Total hemoglobin and HbA1c concentrations are determined. 
Total hemoglobin is measured colorimetrically. The percentage of HbA1c 
is determined immunoturbidimetrically. The ratio of both these levels 
gives the final percent HbA1c result. 
 
EDTA collected blood is hemolysed with hemolysis reagent in the 
predilution cuvette. This leads to reduction in osmotic pressure which 
lyses the erythrocytes. Lysis of erythrocytes releases the haemoglobin. It 
is degraded by the proteolytic action of the enzyme pepsin. This renders 
the beta-N terminal structures more available for the immunoassay.  
 
In the hemolysate, a colorimetric method helps in the 
determination of total haemoglobin. This is done on the basis of 
production of a brownish-green chromophore. This occurs in alkaline 
detergent solution using a cyanide free method. 
 The intensity of colour formed is directly proportional to the total 
hemoglobin concentration present in the sample. The concentration is 
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determined by sensing the increase in absorbance at 552nm. A fixed 
factor that is obtained from the primary calibrator chlorohemin calculates 
the test results. 
 
Turbidimetric method to measure HbA1c is done using monoclonal 
antibodies which are present attached to latex particles. The monoclonal 
antibodies bind the amino terminal fragments of HbA1c. The unbound 
free antibodies agglutinate with an artificial polymer. The change in 
turbidity is inversely related to the quantity of bound glycated proteins. 
This is measured turbidimetrically at 552nm. 
 
Pippetting parameters for measuring Hb: 
 
REAGENT Volume Diluents (H2O) 
Reagent 1 120 µL - 
Sample 6 µL 0 
Total volume 126 µL - 
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Pipetting parameters for measuring HbA1c: 
 
REAGENT Volume Diluents (H2O) 
Reagent 1 120 µL - 
Sample 6 µL 0 
Standard reagent 24 µL 0 
Total volume 150 µL - 
 
The measuring range for HbA1c lies between 0.3– 2.6 g/dL. This 
corresponds to a measuring range of 2-17% HbA1c at a typical 
hemoglobin concentration of 15 g/dL. 
 
The end result of HbA1c is expressed in percentage and is calculated 
from HbA1c/Hb ratio. 
According to IFCC 
• HbA1c(%) = (HbA1c/Hb)*100 
 
  
71 
 
5. Statistical analysis: 
The data obtained after estimation of plasma total thiols, hsCRP 
and HbA1c in two groups were statistically analyzed using SPSS 
software version 19. 
Independent t test was used to analyze plasma total thiols, hsCRP 
and HbA1c levels between the two study population. 
Pearson correlation coefficient was used to find out the correlation 
existing between plasma total thiols and hsCRP with HbA1c. 
Since plasma total thiols and hsCRP levels were not normally 
distributed, Spearman`s rank correlation coefficient was done. 
 
 
 
 
 
 
 
 
72 
 
6. Results: 
 
Fig 6.1: Age distribution among study groups 
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TABLE 1: MEAN AGE OF STUDY POPULATION 
 
                                          AGE IN YEARS 
   
Diabetic 
patients 
Diabetic patients with 
cardiac complications 
MEAN±SD 52.57±11.51 55.70±10.12 
p value          0.116 (Not significant)  
 
Fig 6.2: Sex distribution among study groups 
 
 
 
62
58 Males 
Females
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Fig 6.3: Sex distribution among study group 
 
According to chi-square test, p value was found to be 0.715 (Not 
significant) 
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Fig 6.4:  Duration of diabetes among study population  
 
 
 
 
Diabetic without cardiac 
complications 
Diabetic with cardiac 
complications 
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Fig 6.5: HbA1c levels in study group 
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Fig 6.6: Frequency distribution of glycemic control in the study 
population 
 
 
                                    HbA1c levels 
 
< 7 % is good glycemic control (51) 
 
           > 7 % is poor glycemic control (69) 
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Fig 6.7: hsCRP levels in study population  
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Fig 6.8: Frequency distribution of hsCRP levels in type 2 diabetic 
patients without complications based on Framinghams risk score 
 
 
                                     hsCRP levels (mg/L) 
Risk stratification for cardiovascular events 
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1 – 3 mg/L – Medium risk 
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Fig 6.9: Levels of total plasma thiols in study population  
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TABLE 2: Comparison of duration of diabetes mellitus, HbA1c, 
hsCRP, plasma total thiols between two groups 
  
 
Group Mean 
Std. 
Deviation 
 
Significance(2 
tailed) 
 Duration 1 6.58 6.304  
2 7.23 6.390 0.576 
HbA1c 1 7.6935 1.93539  
2 8.3778 1.79847 0.047 
hsCRP 1 .2885 .26758  
2 3.1970 5.83335 0.000187 
Thiols 1 493.7917 204.10390  
2 517.8683 214.74843 0.530 
 
Group 1: Type 2 diabetic patients without cardiac complications 
Group 2: Type 2 diabetic patients with cardiac complications 
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TABLE 3: Correlation  of hsCRP levels with duration of diabetes, 
HbA1c and protein thiols. 
 
 hsCRP r value p value 
Duration -0.009 0.926 
HbA1c 0.216 0.018 
Thiols 0.373 < 0.001 
 
 
TABLE 4: Correlation of protein thiol levels with duration of 
diabetes, HbA1c and hsCRP 
 
Thiols  r value p value 
Duration -0.104 0.258 
HbA1c 0.369 < 0.001 
hsCRP 0.373 < 0.001 
 
 
 
83 
 
 
Fig 6.10: Correlation of HbA1c levels with hsCRP in study         
population 
 
 
 
p value  0.018 
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Fig 6.11:  Correlation of plasma total thiols with hsCRP in study 
population 
 
 
p value < 0.001 
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Fig 6.12:  Correlation of plasma total thiols with HbA1c in study 
population 
 
 
p value < 0.001 
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Fig 6.13:  Correlation of plasma total thiols with diabetic patients 
with poor glycemic control (HbA1c >7%) in study population 
 
 
p value  0.005 
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Fig 6.14:  Correlation of hsCRP levels with duration of diabetes 
mellitus in study population 
 
 
p value 0.926 
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Fig 6.15:  Correlation of plasma total thiol levels with duration of 
diabetes mellitus in study population 
 
 
p value 0.258 
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Fig 6.16:  Correlation of HbA1c levels with duration of diabetes mellitus 
in study population 
 
 
p value 0.73 
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7. Discussion:  
      Type 2 diabetes mellitus is a chronic metabolic disease and is 
associated with numerous micro-vascular and macro-vascular 
complications. This reduces the life expectancy of the patients by ten 
years. Various studies have shown the relationship between oxidative 
stress, inflammation and the pathogenesis of type 2 diabetes mellitus, 
implicating their role in the occurrence of complications
85, 86
. 
Cardiovascular complications have a major role in increasing the 
morbidity and mortality in type 2 diabetes mellitus patients
87
. Persistent 
hyperglycemic state is known to induce Oxidative stress which in turn 
has been shown to cause endothelial dysfunction .This initiates the events 
leading to the pathogenesis of micro and macro-vascular diseases. 
Oxidative stress is known to increase the expression of pro-inflammatory 
markers and pro-coagulant factors. It also induces apoptosis and impairs 
the release of nitric oxide
88
. 
 This study was done to assess the oxidant and inflammatory status 
in type 2 diabetes mellitus patients with and without cardiac 
complications, by measuring their plasma protein thiols and hsCRP 
levels. I have also tried to find out if there is a correlation existing 
between these two biochemical parameters.  
91 
 
Fig 6.1 shows that type 2 diabetic patients selected with cardiac 
complications were more in 60 to 70 years of age. So independent t test 
was done to analyze and account for age as a confounding factor and 
negate it if found to be significantly interfering with the study. But on 
statistical analysis, the p value was found to be 0.116 which was not 
significant. 
Sex distribution of the number of patients was found to be almost 
equal among the two groups. Chi square test was done for the same and 
the p value was found to be 0.715 which was also not significant. 
Type 2 diabetic patients should undergo screening for diabetic 
complications as soon as they are diagnosed and yearly thereafter. The 
duration of diabetes mellitus from the time of diagnosis has a great 
influence on the development of complications. 
Previous studies have shown that the development and prevalence 
of complications positively correlate with the duration of disease, 
irrespective of the patient`s age 
89, 90, 91
. In this current study most of the 
diabetic patients without complications had been suffering from the 
disease for less than ten years. Diabetic patients with cardiac 
complications have had a longer duration of diabetes mellitus and the p 
value between the two groups was found to be 0.576 which is not 
statistically significant. 
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ADA has approved HbA1c ≥ 6.5% as the criteria for diagnosing 
diabetes mellitus. According to UKPDS study, diabetic complications can 
be prevented with good glycemic control
92
.Stratton IM et al had shown 
that degree of hyperglycemia measured by plasma glucose levels or 
glycated haemoglobin (HbA1c) was significantly associated with the 
incidence of cardiovascular complications. They have concluded that 
14% reduction in myocardial infarction and 37% reduction in 
microvascular complications in diabetic patients would be possible, with 
1% reduction in average HbA1c levels
93
. 
In this study, most of the HbA1c values of type 2 diabetic patients 
without complications were between 6-8 %. Findings in this study also 
correlate with other studies. Independent t test was done and the p value 
of HbA1c levels between the two groups found to be 0.047 which was 
statistically significant. 
C - reactive protein though an acute phase protein when measured 
through high sensitive assays, is fairly specific for the prediction of 
cardiovascular diseases. The role of hsCRP in atherosclerosis has already 
been studied. hsCRP being a part of innate immune response, activates 
complement pathway and stimulates the expression of adhesion 
molecules. It also recruits monocytes and enhances atherosclerosis. Rise 
in CRP level is also associated with endothelial dysfunction. According 
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to Sanchez et al, in type 2 diabetic patients with acute coronary syndrome   
hsCRP can be used as a marker for predicting cardiovascular death
57
. 
 
American Heart association has set hsCRP cut points to be less 
than 1 mg/L, 1 - 3 mg/L, and greater than 3mg/L which correspond to 
low-risk, medium-risk, and high risk group’s respectively
56
. Out of the 60 
diabetic patients without cardiac complications, 58 patients fall under low 
risk and 2 patients fall under medium risk groups. 
 
     Mohan et al in Chennai Urban Rural Epidemiology Study (CURES), 
have found that diabetic subjects with Coronary artery disease (CAD) had 
higher CRP levels when compared to diabetic subjects without CAD and 
non diabetic subjects
94
. Baig et al in a study has got a similar finding that 
patients with diabetic complications had higher hsCRP levels compared 
to those without complications and these values are far higher than the 
non diabetic subjects (p<0.001)
95
.  
 
The results of this current study have been supported by the above 
mentioned studies. In type 2 diabetic patients who had cardiac 
complications, hsCRP values were markedly elevated when compared to 
those without complications expressing a p value of 0.0001(highly 
significant). 
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Reactive oxygen species (ROS) can induce oxidative modification 
of proteins directly or indirectly by the by-products of oxidative stress. As 
a result protein carbonyl derivatives are formed which are considered to 
be the most used biomarkers for oxidative tissue damage. Early 
formation, greater strength and longer life span is the reason for protein 
oxidation products being increasingly used as markers instead of lipid 
peroxidation products in the demonstration of oxidative imbalance. The 
estimation of plasma total thiol will reveal excess free radical generation 
during oxidative stress. Protein thiols scavenge oxidants that initiate 
peroxidation. The thiol (–SH) moiety of cysteine is very much susceptible 
to oxidative attack and this results in the formation of disulfide bonds and 
thiyl radicals. Rise in oxidative protein damage and reduced antioxidative 
defense mechanisms are thought to be the primary pathology behind the 
development of diabetic complications 
96
. 
 
Patients with CAD are known to have higher malondialdehyde 
(MDA) and lower total plasma protein thiol levels than the controls; 
MDA and total thiols represent the oxidative damage products of lipids 
and proteins respectively
97
. Jaiprakash et al have studied the plasma thiol 
levels in three groups namely control, diabetic patients per se and diabetic 
people with end stage renal disease (ESRD). The results showed that 
plasma thiol concentration was significantly decreased (p value < 0.005) 
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in diabetic patients without ESRD when compared with controls 
98
.There 
was also a significant rise in plasma thiols in diabetic patients with end 
stage renal disease when compared to controls which concurred with 
other studies
99, 100
.  
 
  Rama Srivatsan et al also have studied protein thiol levels in three 
groups namely controls, diabetic and diabetic people with microvascular 
complications. According to that study there was no significant difference 
in protein thiol concentration between control and type 2 diabetics and 
also with type 2 DM with complications (P=0.79,P=0.55)
101
. Since 
cardiovascular complications contribute much to the mortality of  type 2 
diabetic patients we estimated the total plasma thiols in patients with  
type 2 diabetes mellitus with and without cardiac complications and 
found that there was no statistical significance (p value, 0.530)between 
the two groups. 
 
The Insulin Resistance Atherosclerosis Study concluded that 
insulin resistance is related to CRP levels, fibrinogen and plasminogen 
activator inhibitor-1 (PAI-1). Rise in PAI-1 and CRP levels are predictors 
of the development of type2 diabetes
102
.  
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Another study has correlated hsCRP with HbA1c levels in 
overweight type 2 diabetic female patients
103
.  Bahceci M et al analysed  
high sensitivity CRP  levels in Type 2 diabetic  men without coronary 
heart disease , non-diabetic CHD patients and T2DM patients with CHD. 
He also concluded that there is a positive correlation between serum hs-
CRP and HbA1c levels
104
. Finding of this current study also substantiates 
the results of previous studies. Pearson correlation shows a positive 
correlation between glycated  haemoglobin (HbA1c) levels and hsCRP 
with r value 0.216.p value is found to be 0.018 which is statistically 
significant. 
 
Previous studies have shown that measurement of intracellular and 
extracellular aminothiol compounds will describe the effect of oxidative 
stress in the body
105
. According to a study by Salman Ashfaq 
measurement of thiols which determines the oxidative stress predicts 
early atherosclerosis, which is measured by carotid intima- media 
thickness
106
. The current study and the analysis of the results suggests a 
very significant positive correlation between the hsCRP levels in plasma 
and the plasma total protein thiols in all the subjects who have diabetes 
with or without complications of diabetes with p value of < 0.001. This is 
suggestive of the fact that inflammatory status and oxidative stress are 
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proven concepts behind pathogenesis of diabetes, a chronic disease of 
mankind.  
 
hsCRP is an established marker of inflammation and infections 
while change in thiol levels are noted in many studies involving stress 
induced due to oxidative changes because of persistent hyperglycemia. 
 
One study has shown that poor glycemic control due to persistent 
hyperglycemia causes glycation of proteins leading to increased oxidative 
damage of proteins and this increases the rate of development of diabetes 
related complications
107
. 
 
The current study and the analysis of the results also suggests a 
very significant positive correlation between the blood levels of HbA1c 
and the plasma total protein thiols in all the subjects who have diabetes 
with or without complications of diabetes with p value of < 0.001. 
Further analysis of thiol levels with glycemic status shows that poor 
glycemic control with HbA1c > 7 % shows a significant positive 
correlation with thiol levels having a p value of 0.005 than with that of 
good glycemic control. 
 
HbA1c level in the blood is not only a direct predictor of the risk of 
complications in diabetes, but also a prognostic marker and treatment 
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guide for Diabetes and hence the results are suggestive of the fact that as 
HbA1c levels rise, the severity of complications also rise which indirectly 
suggests the inflammatory status /oxidative stress state is prevalent in the 
patients under study.  
 
Change in thiol levels are noted in many studies due to oxdative 
stress resulting from persistent hyperglycemia. In this current study the 
change in thiols is in the upward direction which facilitates the idea of 
induction in the synthesis of thiols to counter the oxidants. Some studies 
on the other hand have shown a fall in thiol levels due to oxidative 
damage which has been explained by consumption and near exhaustion of 
thiols in the process of neutralizing the oxidant radicals
108
. 
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8. Conclusion: 
Diabetes mellitus is a group of metabolic disease presenting with 
symptoms of hyperglycemia which may be either due to defective 
secretion of insulin by pancreas or resistance to insulin action or both. 
The current study tried to estimate plasma total thiols, hsCRP and HbA1c 
levels in type 2 diabetic patients without complications and type 2 
diabetic patients with cardiac complications. This study also tried to find 
out if there is a correlation existing between each other in the study 
groups. 
• The results suggest that there is a significant elevation in HbA1c 
and hsCRP levels in type 2 diabetic patients with cardiac 
complications when compared to diabetics without complications. 
• No significant differences in plasma total thiols have been noted 
between the two groups. 
• There is a very significant positive correlation between hsCRP, 
plasma total thiols and HbA1c levels in type 2 diabetic patients. 
The findings of this study suggest that poor glycemic control, 
oxidative stress and inflammation contribute to the pathogenesis of 
diabetic complications. 
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Limitations of the study: 
 
• Small sample size due to financial constraints. 
• Type of treatment given for type 2 diabetic patients with and 
without complications would differ and the treatment options 
within the same group may be different. The effect of drugs used is 
not taken into consideration. If those drugs per se had a say on the 
inflammatory status of the patient it would not be showing up on 
this current study. 
• Use of statins in diabetic patients with cardiac complications may 
alter the inflammatory status of the patient. 
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9. Summary: 
Diabetes mellitus is a growing non communicable disease 
presenting with symptoms of hyperglycemia due to reduced insulin 
secretion, defective insulin action or a combination of both. If not 
detected earlier patients may present with diabetic complications. As the 
duration of diabetes mellitus increases, the risk of developing 
complications also increases. It is associated with a number of micro-
vascular and macro-vascular complications which adds to the burden of 
the disease.  Diabetes mellitus is considered to be coronary heart disease 
equivalent. Cardiovascular diseases and mortality due to it are much 
greater in people with type 2 diabetes mellitus than that of non- diabetic 
individuals. 
Many studies have shown the role of oxidative stress and 
inflammation in type 2 diabetes mellitus and its complications with the 
help of oxidative and inflammatory biomarker assays. Few studies have 
been conducted to correlate plasma total thiols between type 2 diabetes 
mellitus patients with and without cardiac complications. 
 This study was done to measure plasma total thiols, hsCRP and 
HbA1c levels in type 2 diabetic patients without complications and type 2 
diabetic patients with cardiac complications.  This study also tried to find 
out if there is a correlation if any, existing between them in the study 
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population.HbA1c, plasma total protein thiols, plasma hsCRP were 
estimated in 60 type2 diabetic patients without complications and 60 
type2 diabetic patients with cardiac complications. Plasma total protein 
thiols was estimated spectrophotometrically by using Dinitrobenzene 
(DTNB)-Ellman’s method. Plasma hsCRP by particle enhanced 
turbidimetric assay.HbA1c by turbidimetric inhibition immunoassay.  
HbA1c (p - 0.047) and plasma hsCRP(p- 0.0001) were 
significantly higher in type2 diabetic patients with cardiac complications. 
There is also a very significant positive correlation between the blood 
levels of HbA1c with the plasma total protein thiols (p value < 0.001) and 
hsCRP (p value 0.018). In addition there is a very significant positive 
correlation between the plasma levels of hsCRP and the plasma total 
protein thiols with a p value of < 0.001.  
Role of oxidative stress and inflammation are established in the 
pathogenesis of diabetic complications and persistent hyperglycemia 
contributes to these changes. This is the reason for increased HbA1c and 
plasma hsCRP in type 2 diabetic patients with cardiac complications. 
Change in thiol levels are due to the increased synthesis to compensate 
for the loss incurred during neutralization of the oxidants. 
 
 
103 
 
 
10. Future scope of the study: 
 
• Many of the disadvantages can probably be negated if the sample 
size is substantially increased 
• Plasma total thiols and hsCRP may be used as a prognostic marker 
for survival of the patient 
• Genetic analysis for the proteins like CRP might throw some light 
into the pathogenesis of type 2 diabetes mellitus and its 
complications. 
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ANNEXURE 
 
Master chart for Type 2 Diabetic patients without complications 
 
S.No Age Sex hsCRP Duration HbA1C Thiols 
1 63 M 0.1 7 5.8 249.75 
2 42 M 0.16 1 9.71 646 
3 50 F 0.6 8 7.2 609.75 
4 40 F 0.72 1 6.8 272 
5 35 M 0.06 2 11.8 315.25 
6 35 M 0.26 1 6.6 467.5 
7 55 M 0.21 4 8.41 700 
8 75 M 0.09 15 6.65 292 
9 39 M 0.29 2 12.16 816 
10 59 M 0.04 8 6.5 132.5 
11 69 F 0.02 20 6.7 275.25 
12 65 M 0.05 25 6.32 315 
13 37 F 0.08 2 5.9 461.25 
14 55 M 0.21 10 6.9 375 
15 35 F 0.6 2 6.45 463 
16 64 M 0.37 5 7 432 
17 63 F 0.09 3 6.4 351.5 
18 60 M 0.2 8 11.6 830 
19 36 F 0.34 2 5.3 400 
20 56 F 0.36 1 7.4 227.25 
21 65 F 0.07 2 7.2 290.25 
22 49 F 0.35 3 5.7 259.75 
23 45 M 0.23 1 5.2 438 
24 36 M 0.24 8 6.94 949.5 
25 65 F 0.08 10 6.87 286 
26 48 F 0.49 5 9.8 886.25 
27 68 M 0.05 5 7.4 531 
28 52 M 0.03 8 6.39 484.5 
29 56 M 0.14 6 6.5 302 
30 59 M 0.56 1 6.93 475 
  
S.No Age Sex hsCRP Duration HbA1C Thiols 
31 39 M 0.67 3 9.5 532.75 
32 72 F 0.05 8 9.8 620 
33 57 F 1.02 20 12.65 816.5 
34 40 F 0.06 2 6.8 436 
35 38 M 0.16 2 6.1 430.5 
36 38 M 0.51 1 6.46 292 
37 60 M 0.09 10 8.9 633 
38 74 M 0.06 12 9.5 659.75 
39 49 F 0.28 4 6.67 409.75 
40 51 F 0.11 13 11.25 715.25 
41 67 F 0.04 25 6.46 68 
42 44 F 0.35 1 6.5 315.25 
43 35 F 0.19 2 5.67 467.5 
44 58 M 0.52 1 6.3 500 
45 47 M 0.74 12 12 792 
46 59 M 0.77 2 9.24 716 
47 44 M 0.12 4 6.5 432.5 
48 58 F 0.09 1 5.9 275.25 
49 56 M 0.21 1 8.73 515.5 
50 54 F 0.13 5 9.66 661.25 
51 49 F 0.49 8 11.63 975.25 
52 69 M 0.05 25 7.59 402 
53 40 F 1.15 1 6.9 769 
54 58 F 0.09 12 6.82 434 
55 63 M 0.07 9 7.1 463.5 
56 42 F 0.6 5 6.1 627 
57 63 F 0.31 10 6.9 472.75 
58 47 F 0.33 5 6.35 412 
59 64 M 0.86 3 7.8 520 
60 43 F 0.1 12 9.3 730 
 
 
 
 
  
Master chart for Type 2 Diabetic patients with Cardiac 
complications 
 
 
S.No Age Sex hsCRP Duration HbA1C Thiols 
1 55 F 0.09 6 7.78 645 
2 64 M 1.13 16 9.29 378 
3 60 F 0.08 1 6 285 
4 53 M 0.19 3 9.4 180 
5 59 M 0.1 8 7.47 525.75 
6 60 F 0.12 7 11.08 216 
7 58 F 0.22 20 11.8 374 
8 67 M 0.22 2 6.8 420.5 
9 60 F 0.21 5 6.61 365 
10 48 M 0.23 8 7.8 492.25 
11 64 M 0.19 9 7 262.5 
12 45 F 19.05 6 10.4 859 
13 43 M 6.87 5 8.85 426 
14 65 M 20.9 7 10.6 978 
15 65 F 0.43 6 12.44 836 
16 46 M 0.09 9 7 418 
17 50 F 0.24 3 8.5 556.5 
18 56 M 0.25 4 7.89 502.6 
19 57 F 0.11 8 7.5 312.5 
20 63 M 0.42 2 6.6 668 
21 40 F 3.61 1 9.2 473 
22 55 M 7.22 4 12.43 159.75 
23 42 M 0.12 3 9.8 438.75 
24 64 F 0.78 6 8.9 757 
25 50 M 6.66 13 11.12 315 
26 50 F 1.92 4 9.6 732.5 
27 50 M 4.6 2 7.38 411 
28 68 M 0.3 15 8.4 394 
29 58 F 0.16 4 5.72 375 
30 60 M 0.28 5 7.3 463 
  
S.No Age Sex hsCRP Duration HbA1C Thiols 
31 55 F 0.62 3 6.2 432 
32 35 F 14.12 1 12 918 
33 65 M 0.48 8 8.3 351.5 
34 46 F 0.18 6 10.8 367 
35 65 M 0.62 10 6.56 547 
36 37 M 4.19 6 12 658 
37 43 M 0.03 7 7.12 656 
38 49 M 7.58 2 9.02 694.25 
39 64 F 4.3 3 7.9 335 
40 46 M 0.18 1 8.09 630 
41 60 M 1.99 6 7.49 721 
42 51 F 3.01 4 9.38 351 
43 64 F 0.15 6 6.85 400 
44 67 M 0.11 12 7.29 221 
45 55 F 0.38 4 8.69 628 
46 68 F 21.55 7 6.76 828.25 
47 52 F 3.94 20 6.8 856 
48 60 F 0.28 8 7.2 531 
49 35 F 7.6 4 11.15 543 
50 61 M 0.43 3 7.35 446 
51 65 F 0.21 20 7.35 443 
52 43 F 0.03 9 7.8 184.5 
53 72 M 3 17 5.58 778 
54 48 F 0.47 1 10.3 719.25 
55 46 M 0.08 2 8.7 380 
56 74 M 25.77 1 7.81 980 
57 66 M 0.56 15 6.59 555.25 
58 69 M 10.66 35 7.33 297 
59 71 F 0.49 20 7 425.25 
60 35 F 2.02 1 6.6 976.25 
 
 
 
  
DATA COLLECTION TOOL (QUESTIONNAIRE) 
1. Patient's name  : 
2. Patient's ID   : 
3. Age    : 
4. Sex    : 
5. History of illness  : 
     5.1.  Diabetes      :    Type 1           Type 2 
     5.2.  Duration of diabetes :  
     5.3.  Hypertension   :        1. Yes        2.   No 
     5.4.  Smoking history   : 
               If yes, pack years  : 
     5.5. H/O myocardial infarction/Angina/LV    dysfunction:                           
                                                1. Yes        2.   No 
5.6. Vision    :                
5.7. Motor/sensory functions :     
5.8. History of any other illness   :    1. Yes        2.   No 
             If yes, Details :   
5.9. Details of treatment  : 
5.10. Lab values   : 
 
